NON HODGKIN LYMPHOMA (NHL)
Clinical trials for NON HODGKIN LYMPHOMA (NHL) explained in plain language.
Never miss a new study
Get alerted when new NON HODGKIN LYMPHOMA (NHL) trials appear
Sign up with your email to follow new studies for NON HODGKIN LYMPHOMA (NHL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug NB02 tested for tough lymphoma cases
Disease control Recruiting nowThis early-phase trial tests a new drug called NB02 (posseltinib) in about 9 adults with certain types of Non-Hodgkin lymphoma (follicular, mantle cell, or marginal zone) that have returned or not responded to at least two prior treatments. The main goals are to find a safe dose …
Matched conditions: NON HODGKIN LYMPHOMA (NHL)
Phase: PHASE1 • Sponsor: NOBO Medicine • Aim: Disease control
Last updated May 17, 2026 03:01 UTC
-
New injection shows promise for tough blood cancers in early trial
Disease control Recruiting nowThis early-phase study is testing a new treatment called OriV508 for people with multiple myeloma or non-Hodgkin lymphoma that has come back or not responded to standard therapy. The main goals are to check safety and find the right dose. About 40 adults aged 18-75 will take part…
Matched conditions: NON HODGKIN LYMPHOMA (NHL)
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated May 17, 2026 03:00 UTC
-
New immune therapy targets Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-phase study tests a new treatment called LV009 injection for people with certain blood cancers (non-Hodgkin lymphoma and acute lymphoblastic leukemia) that have not responded to standard therapy or have returned. The treatment uses the patient's own immune cells, modif…
Matched conditions: NON HODGKIN LYMPHOMA (NHL)
Phase: EARLY_PHASE1 • Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Double-targeting CAR-T cells take on hard-to-treat blood cancers
Disease control Recruiting nowThis study tests a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells. It is for adults with certain B cell blood cancers (like lymphoma or leukemia) that have not responded to other treatments. The goal is to see if these specially engineere…
Matched conditions: NON HODGKIN LYMPHOMA (NHL)
Phase: PHASE1, PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated May 12, 2026 13:41 UTC